Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEnveric Biosciences Inc

Enveric Biosciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.424 USD 0.02 ( 1.71%)
Last update at 2026-11-06T21:26:00Z
VOLUME
10393
Market Cap
6.36M

Momentum Score

…

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.38
Low
1.46
High
52 Week Price Range
0.65
Low
4.78
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Enveric Biosciences is a clinical-stage biopharmaceutical firm developing psychedelic-inspired and related therapies for mental health and oncology supportive care. Long-term growth drivers include clinical trial progress, expanding regulatory acceptance of psychedelic-assisted treatments, and partnerships or licensing to advance candidates into late-stage development. The company's early-stage pipeline offers exposure to an emerging therapeutic area that may benefit investors seeking innovative neuropsychiatric and supportive-care opportunities.

Principal investment risks include unproven clinical efficacy, regulatory and reimbursement uncertainty, high cash burn with likely dilution, and strong scientific and competitive execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.40
Dividend Yield
-
Revenue TTM
35.41M
Revenue Per Share
37.68
Gross Profit TTM
8.15M
Debt / Equity
0.00
ROE
-197.47%
Net Debt
-2.29M
ROCE
-726.43%
Diluted EPS TTM
-6.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -19.96M -56.43M -6.86M -5.22M -10.55M
Minority interest -0.03M - - - -
Net income -18.47M -48.98M -6.39M -5.60M -16.90M
Selling general administrative 11.61M 20.50M 5.44M 12.21M 10.79M
Gross profit - -656.64M 8.15M 8.15M 8.98M
Reconciled depreciation 0.44M 0.68M 0.12M 2.27M 2.90M
Ebit -27.42M -64.62M -5.62M -6.32M -4.63M
Ebitda -19.53M -26.39M -6.42M -4.06M -1.72M
Depreciation and amortization 7.89M 38.24M -0.80M 2.27M 2.90M
Operating income -27.42M -64.62M -5.62M -6.32M -7.15M
Other operating expenses 19.96M 25.94M 5.62M 46.24M 47.71M
Interest expense 0.01M 0.01M 0.45M 0.69M 0.73M
Tax provision -1.49M -7.45M - 0.39M 6.35M
Net interest income -0.01M -0.01M -0.45M -0.69M -0.73M
Income tax expense -1.49M -7.45M -0.48M 0.39M 6.35M
Total revenue 0.00M 0.00M 39.91M 39.91M 43.00M
Total operating expenses 19.96M 25.94M 5.62M 14.48M 13.70M
Cost of revenue - 656.64M 31.76M 31.76M 34.01M
Total other income expense net 7.46M 8.19M -1.25M 1.11M -5.10M
Net income from continuing ops -18.47M -48.98M -6.86M -5.60M -16.90M
Net income applicable to common shares - -48.98M -6.86M -2.41M -1.92M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6.12M 19.55M 26.72M 4.10M 25.01M
Intangible assets 0.21M 0.38M 6.92M 1.82M 3.58M
Other current assets 0.50M 0.71M 0.38M 0.70M 0.78M
Total liab 2.34M 4.00M 4.41M 0.68M 14.38M
Total stockholder equity 3.77M 14.67M 22.31M 3.42M 10.62M
Other current liab 1.12M 3.47M 1.29M 0.68M 4.81M
Common stock 0.03M 0.02M 0.33M 0.10M 0.03M
Capital stock 0.03M 0.02M 0.33M 0.13M 0.03M
Retained earnings -96.50M -79.21M -60.74M -11.76M -40.51M
Other liab - - 2.26M - -
Good will - 0.00M 1.59M 13.73M 13.73M
Other assets 0.00M - - - -
Cash 2.29M 17.72M 17.36M 1.58M 0.43M
Total current liabilities 2.34M 4.00M 2.08M 0.68M 14.38M
Net debt -2.29M -17.66M -17.18M -1.58M 4.45M
Short term debt - 0.06M 0.11M 4.88M 4.88M
Short long term debt - - - - 4.88M
Short long term debt total - 0.06M 0.18M 4.88M 4.88M
Other stockholder equity 100.82M 94.40M 82.75M 15.22M 51.04M
Property plant equipment - - 0.47M - -
Total current assets 3.01M 18.43M 17.74M 2.28M 7.60M
Net tangible assets - - 13.79M 1.57M -1.81M
Net receivables 0.22M - - 6.38M 6.38M
Accounts payable 1.22M 0.46M 0.68M 0.68M 4.70M
Accumulated other comprehensive income -0.57M -0.54M -0.03M -0.18M 0.06M
Common stock total equity - - - 0.03M -
Non currrent assets other 0.57M - - - -
Non current assets total 3.10M 1.12M 8.98M 1.82M 17.41M
Capital lease obligations 0.00M 0.06M 0.18M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.58M 2.19M -0.04M -0.28M -3.64M
Change to liabilities - 0.38M 0.27M 0.92M 0.15M
Total cashflows from investing activities - 2.19M -0.04M -0.04M -0.04M
Net borrowings - - 1.67M 0.56M 0.56M
Total cash from financing activities 18.18M 24.90M 5.53M 1.80M 2.69M
Change to operating activities - 0.80M -0.64M 0.10M -0.01M
Net income -18.47M -48.98M -6.86M -6.03M -16.90M
Change in cash 0.37M 15.78M 1.53M -0.94M -3.51M
Begin period cash flow 17.36M 1.58M 0.04M 1.37M 4.88M
End period cash flow 17.72M 17.36M 1.58M 0.43M 1.37M
Total cash from operating activities -17.15M -11.46M -3.89M -2.45M -2.57M
Issuance of capital stock 17.22M 21.61M 0.49M 2.12M 6.33M
Depreciation 0.44M 0.68M 0.12M 2.27M 2.90M
Dividends paid - - - - 2089151.00M
Change to account receivables - - 1.49M 1.49M 0.97M
Sale purchase of stock - - - - 2089151.00M
Other cashflows from financing activities 0.96M 3.29M 5.23M 1.00M -1.66M
Change to netincome - 35.65M 2.94M 0.67M 1.06M
Capital expenditures 0.58M 0.86M 0.04M 0.08M 0.19M
Change in working capital -0.22M 1.19M -0.37M 1.74M -1.03M
Stock based compensation 2.62M 12.60M 1.98M 0.59M 1.25M
Other non cash items -0.01M 30.51M 1.25M -1.41M 4.86M
Free cash flow -17.73M -12.32M -3.93M -2.54M -2.57M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ENVB
Enveric Biosciences Inc		 0.02
1.71%		 1.42 - 23.09 0.08 3.73 1.76 -0.01
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Enveric Biosciences Inc

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

4851 Tamiami Trail N, Naples, FL, United States, 34103

239 302 1707

https://www.enveric.com

7

Name Title Year Born
Dr. Joseph Edward Tucker Ph.D. CEO & Director 1968
Mr. Avani V. Kanubaddi Pres & COO 1973
Dr. Peter J. Facchini Ph.D. Chief Innovation Officer 1963
Dr. Ibrahim Dagher M.D. Chief Medical Officer 1969
Mr. Robert Dickey IV, M.B.A. Interim Chief Financial Officer 1956
Dr. Peter J. Facchini Ph.D. Chief Innovation Officer 1964
Mr. Kevin M. Coveney CPA Chief Financial Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…